A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

The experimental drug lepodisiran, developed by Eli Lilly, significantly lowered levels of the genetically inherited heart ...

"If India counters with its own tariffs, it could disrupt supply chains, increase costs, and slow market expansion for both ...

Eli Lilly's experimental drug, lepodisiran, showcased remarkable efficacy in reducing lipoprotein(a) levels, a heart disease risk factor, by up to 95% in a midstage trial. The innovative treatment ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

The investigational aldosterone synthase inhibitor lorundrostat effectively lowered 24-hour BP for adults with well-treated, uncontrolled and “true” treatment-resistant hypertension, according to data ...

American Century Companies Inc. gave Amgen a financial haircut, slashing its stake by 46.3% and cashing in $36.76 million.

Korea Investment CORP quietly added a few thousand shares of ConocoPhillips, raising its stake to a cool $104.59 million.